74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
KalVista Pharmaceuticals Inc
Closed
SectorHealthcare
12.87 3.62
Overview
Share price change
24h
Min
12.3
Max
13.1
Income | -6.2M -49M |
|---|---|
EPS | -0.92 |
Profit margin | -3,702.322 |
Employees | 150 |
EBITDA | 4.4M -41M |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +112.58% upside |
Next Earnings | 10 Jul 2025 |
|---|
Market Cap | 4.6M 597M |
|---|---|
Previous open | 9.25 |
Previous close | 12.87 |
Technical Score
By Trading Central
Confidence
Strong Bullish Evidence
KalVista Pharmaceuticals Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
KalVista Pharmaceuticals Inc Forecast
Price Target
By TipRanks
112.58% upside
12 Months Forecast
Average 27.38 USD 112.58%
High 39 USD
Low 19 USD
Based on 10 Wall Street analysts offering 12 month price targets forKalVista Pharmaceuticals Inc - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About KalVista Pharmaceuticals Inc
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID for pediatric use with HAE; KONFIDENT-S for adolescent and adult patients with type I or type II HAE; and KONFIDENT for a potential oral therapy for HAE attacks. The company is headquartered in Cambridge, Massachusetts.
